PMID- 17427184
OWN - NLM
STAT- MEDLINE
DCOM- 20070814
LR  - 20200930
IS  - 1552-4841 (Print)
IS  - 1552-4841 (Linking)
VI  - 144B
IP  - 4
DP  - 2007 Jun 5
TI  - Identification of two risk haplotypes for schizophrenia and bipolar disorder in 
      the synaptic vesicle monoamine transporter gene (SVMT).
PG  - 502-7
AB  - The synaptic vesicular monoamine transporter (SVMT) plays a key role in 
      monoaminergic neurotransmission determining the size of neurotransmitter 
      vesicular pools available for exocytotic release. Recently, several lines of 
      evidence have suggested that altered functions of SVMT may be involved in the 
      pathogenesis of certain neuropsychiatric diseases, including psychotic and mood 
      disorders. In the present study, we tested the potential involvement of SVMT gene 
      variants in the etiology of schizophrenia and bipolar disorder. Five different 
      SNPs (T440G, C1368T, T2666C, A2683C, and A745G) were included in the analysis 
      covering a region of about 35 kb along the SVMT gene. Analyses were performed in 
      a case-control sample consisting of 88 bipolar patients, 107 subjects with 
      schizophrenia, and 164 controls. Two risk haplotypes for both schizophrenia and 
      bipolar disorder in SVMT gene were identified. Particularly, 2666T-2683A-745G 
      (TAG) and 2666C-2683C-745A (CCA) combinations were significantly more frequent in 
      both bipolar and schizophrenic patients than in controls. UNPHASED package 
      estimated haplotype effects for all patients yielded relative risks of 4.1 
      (95%CI: 1.83-9.21) for TAG combination and 2.336 (95%CI: 1.28-4.26) for CCA 
      haplotype. Conversely, 2666T-2683C-745A (TCA) and 2666C-2683A-745G (CAG) 
      haplotypes seemed to protect against these mental disorders, since the estimated 
      frequency in control chromosomes was 12% whilst such haplotypes were not observed 
      in any bipolar or schizophrenic subject (P < 0.0000). Our results strongly 
      suggest that SVMT gene or certain regions of it may constitute a genetic 
      substrate of susceptibility for both schizophrenia and bipolar disorder.
CI  - (c) 2007 Wiley-Liss, Inc.
FAU - Gutierrez, Blanca
AU  - Gutierrez B
AD  - Unitat d'Antropologia, Facultat de Biologia, Universitat de Barcelona, Barcelona, 
      Spain. blancag@ugr.es
FAU - Rosa, Araceli
AU  - Rosa A
FAU - Papiol, Sergi
AU  - Papiol S
FAU - Arrufat, Francisco J
AU  - Arrufat FJ
FAU - Catalan, Rosa
AU  - Catalan R
FAU - Salgado, Purificacion
AU  - Salgado P
FAU - Peralta, Victor
AU  - Peralta V
FAU - Cuesta, Manuel J
AU  - Cuesta MJ
FAU - Fananas, Lourdes
AU  - Fananas L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med Genet B Neuropsychiatr Genet
JT  - American journal of medical genetics. Part B, Neuropsychiatric genetics : the 
      official publication of the International Society of Psychiatric Genetics
JID - 101235742
RN  - 0 (Genetic Markers)
RN  - 0 (SLC18A2 protein, human)
RN  - 0 (Vesicular Monoamine Transport Proteins)
SB  - IM
MH  - Adult
MH  - Bipolar Disorder/*genetics
MH  - Female
MH  - Genetic Markers
MH  - Genetic Predisposition to Disease
MH  - *Haplotypes
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic
MH  - Risk Factors
MH  - Schizophrenia/*genetics
MH  - Vesicular Monoamine Transport Proteins/*genetics
EDAT- 2007/04/12 09:00
MHDA- 2007/08/19 09:00
CRDT- 2007/04/12 09:00
PHST- 2007/04/12 09:00 [pubmed]
PHST- 2007/08/19 09:00 [medline]
PHST- 2007/04/12 09:00 [entrez]
AID - 10.1002/ajmg.b.30499 [doi]
PST - ppublish
SO  - Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):502-7. doi: 
      10.1002/ajmg.b.30499.